Evidence map›Paper›PMID 34420114›Full record

ArticleAnnals of intensive care2021

Gastrointestinal bleeding in critically ill immunocompromised patients.

Jennifer Catano, Sophie Caroline Sacleux, Jean-Marc Gornet, Marine Camus, Naike Bigé, Faouzi Saliba, Elie Azoulay, Guillaume Dumas, Lara Zafrani

Open access · goldAbstract read
In one paragraph

Article in Annals of intensive care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Jennifer CatanoIntensive Care Unit, Saint-Louis Hospital, Assistance Publique Des Hôpitaux de Paris, Paris, France.
Sophie Caroline SacleuxIntensive Care Unit, Paul Brousse Hospital, INSERM N°1193, Assistance Publique Des Hôpitaux de Paris, Université Paris-Saclay, Villejuif, France.
Jean-Marc GornetGastroenterology Department, Saint-Louis Hospital, Assistance Publique Des Hôpitaux de Paris, Paris, France.
Marine CamusDepartment of Digestive Endoscopy, Saint-Antoine Hospital, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine and Assistance Publique-Hôpitaux de Paris, Paris, France.
Naike BigéIntensive Care Unit, Saint-Antoine Hospital, Assistance Publique Des Hôpitaux de Paris, Paris, France.
Faouzi SalibaIntensive Care Unit, Paul Brousse Hospital, INSERM N°1193, Assistance Publique Des Hôpitaux de Paris, Université Paris-Saclay, Villejuif, France.
Elie AzoulayIntensive Care Unit, Saint-Louis Hospital, Assistance Publique Des Hôpitaux de Paris, Paris, France.
Guillaume DumasIntensive Care Unit, Saint-Louis Hospital, Assistance Publique Des Hôpitaux de Paris, Paris, France.
Lara ZafraniIntensive Care Unit, Saint-Louis Hospital, Assistance Publique Des Hôpitaux de Paris, Paris, France. lara.zafrani@aphp.fr.
Assistance Publique – Hôpitaux de Paris · FRCentre de Recherche Saint-Antoine · FRHIPI - Immunologie humaine, physiopathologie et immunithérapieHôpital Paul-Brousse · FRHôpital Saint-Antoine · FRHôpital Saint-Louis · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute gastrointestinal bleeding (GIB) may be a severe condition in immunocompromised patients and may require intensive care unit (ICU) admission. We aimed to describe the clinical spectrum of critically ill immunocompromised patients with GIB and identify risk factors associated with mortality and severe GIB defined by hemorrhagic shock, hyperlactatemia and/or the transfusion of more than 5 red blood cells units. Finally, we compared this cohort with a control population of non-immunocompromised admitted in ICU for GIB.

resultsRetrospective study in 3 centers including immunocompromised patients with GIB admitted in ICU from January, 1st 2010 to December, 31rd 2019. Risk factors for mortality and severe GIB were assessed by logistic regression. Immunocompromised patients were matched with a control group of patients admitted in ICU with GIB. A total of 292 patients were analyzed in the study, including 141 immunocompromised patients (compared to a control group of 151 patients). Among immunocompromised patients, upper GIB was more frequent (73%) than lower GIB (27%). By multivariate analysis, severe GIB was associated with male gender (OR 4.48, CI95% 1.75-11.42, p = 0.00), upper GIB (OR 2.88, CI95% 1.11-7.46, p = 0.03) and digestive malignant infiltration (OR 5.85, CI95% 1.45-23.56, p = 0.01). Conversely, proton pump inhibitor treatment before hospitalization was significantly associated with decreased risk of severe GIB (OR 0.25, IC95% 0.10-0.65, p < 0.01). Fifty-four patients (38%) died within 90 days. By multivariate analysis, mortality was associated with hemorrhagic shock (OR 2.91, IC95% 1.33-6.38, p = 0 .01), upper GIB (OR 4.33, CI95% 1.50-12.47, p = 0.01), and long-term corticosteroid therapy before admission (OR 2.98, CI95% 1.32-6.71, p = 0.01). Albuminemia (per 5 g/l increase) was associated with lower mortality (OR 0.54, IC95% 0.35-0.84, p = 0.01). After matching with a control group of non-immunocompromised patients, severity of bleeding was increased in immunocompromised patients, but mortality was not different between the 2 groups.

conclusionMortality is high in immunocompromised patients with GIB in ICU, especially in patients receiving long term corticosteroids. Mortality of GIB is not different from mortality of non-immunocompromised patients in ICU. The prophylactic administration of proton pump inhibitors should be considered in this population.

Indexed as

Gastrointestinal bleedingImmunocompromised hostIntensive care unitLymphoma

Identifiers

PMID34420114
PMCPMC8380218
OpenAlexW3194824143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.